COMPASS Pathways plc (CMPS) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped CMPS stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: COMPASS Pathways plc shows promising potential in the healthcare innovation sector specializing in psychedelic therapies. With strong analyst support, recent positive developments in clinical trials, and broad societal acceptance towards mental health solutions, the company is positioned for significant growth. Despite risks associated with regulatory scrutiny and the competitive landscape, the company's innovative therapies and partnerships underscore a bullish outlook. Price targets and market forecasts reflect substantial upside based on sector trends and the company's trajectory. The saved 1-year distribution is P10 $9, P50 $16, and P90 $25.
Last analyzed · Model: gpt-4o
COMPASS Pathways plc Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $9 | Pessimistic plausible scenario |
| P50 | $16 | Median scenario |
| P90 | $25 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
A strong analyst consensus and positive recent developments suggest significant upside potential. However, risks associated with the clinical trial scrutiny remain.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this CMPS analysis generated?
May 29, 2026.
Is this a guaranteed CMPS prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full CMPS stock analysis · CMPS sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.